Literature DB >> 17017557

Surgical therapy for Parkinson's disease.

A L Benabid1, S Chabardès, E Seigneuret, V Fraix, P Krack, P Pollak, R Xia, B Wallace, F Sauter.   

Abstract

High frequency stimulation (HFS) has become the main alternative to medical treatment, due to its reversibility, adaptability, and low morbidity. Initiated in the thalamus (Vim) for the control of tremor, HFS has been applied to the Pallidum (GPi), and then to the subthalamic nucleus (STN), suggested by experiments in MPTP monkeys. STN-HFS is highly efficient on tremor, rigidity and bradykinesia and is now widely applied. Criteria for success are correct patient selection and precise electrode placement. The best outcome predictor is the response to Levodopa. The mechanisms of action might associate inhibition of cell firing, jamming of neuronal message and exhaustion of synaptic neurotransmitter release. The inhibition of glutamate STN release could be neuroprotective on nigral cells. Animal experiments support this hypothesis, not contradicted by the long-term follow up of patients. Neuroprotection might have considerable impact on the management of PD patient and warrants clinical trials.

Entities:  

Mesh:

Year:  2006        PMID: 17017557     DOI: 10.1007/978-3-211-45295-0_58

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  3 in total

Review 1.  Subthalamic nucleus versus pedunculopontine nucleus stimulation in Parkinson disease: synergy or antagonism?

Authors:  M U Ferraye; B Debû; V Fraix; P Krack; S Charbardès; E Seigneuret; A-L Benabid; P Pollak
Journal:  J Neural Transm (Vienna)       Date:  2011-06-22       Impact factor: 3.575

2.  Method for patient-specific finite element modeling and simulation of deep brain stimulation.

Authors:  Mattias Aström; Ludvic U Zrinzo; Stephen Tisch; Elina Tripoliti; Marwan I Hariz; Karin Wårdell
Journal:  Med Biol Eng Comput       Date:  2008-10-21       Impact factor: 2.602

3.  The subthalamic nucleus keeps you high on emotion: behavioral consequences of its inactivation.

Authors:  Yann Pelloux; Julie Meffre; Elodie Giorla; Christelle Baunez
Journal:  Front Behav Neurosci       Date:  2014-12-05       Impact factor: 3.558

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.